AA
ZNTL icon

ALPS Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

ALPS Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-55,033
Closed -$87.5K – 1062
2025
Q1 		$87.5K Sell
55,033
-2,554
-4% -$5.51K ﹤0.01% 982
2024
Q4 		$174K Buy
57,587
+1,371
+2% +$4.49K ﹤0.01% 975
2024
Q3 		$207K Buy
56,216
+802
+1% +$2.92K ﹤0.01% 978
2024
Q2 		$227K Buy
55,414
+5,360
+11% +$59.9K ﹤0.01% 942
2024
Q1 		$789K Buy
50,054
+2,147
+4% +$29.5K 0.01% 534
2023
Q4 		$726K Sell
47,907
-4,218
-8% -$61.5K 0.01% 553
2023
Q3 		$1.05M Buy
52,125
+8,407
+19% +$213K 0.01% 431
2023
Q2 		$1.23M Buy
+43,718
New +$1.05M 0.01% 420

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

ALPS Advisors's ZNTL Position: Q2 2025 in Review

ALPS Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 55,033 shares — an estimated $87.5K sold.

ALPS Advisors first reported a position in ZNTL in Q2 2023 and held it in 8 quarters. The position peaked at $1.23M in Q2 2023. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • ALPS Advisors reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • ALPS Advisors sold 55,033 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $87.5K.
  • ALPS Advisors first reported a position in Zentalis Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • ALPS Advisors's Zentalis Pharmaceuticals position peaked at $1.23M in Q2 2023.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.